Patents by Inventor Oliver Krämer

Oliver Krämer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors
    Patent number: 11384076
    Abstract: The present invention relates to small molecule compounds of formula (I) and their use as FLT3 inhibitors for the treatment of various diseases, such as acute myeloid leukemia (AML). The present invention further relates to methods of synthesizing the compounds and methods of treatment.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: July 12, 2022
    Assignees: UNIVERSITÄT REGENSBURG, UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
    Inventors: Siavosh Mahboobi, Andreas Sellmer, Herwig Pongratz, Bernardette Pilsl, Oliver Krämer, Thomas Kindler, Mandy Beyer
  • SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS
    Publication number: 20200190075
    Abstract: The present invention relates to small molecule compounds of formula (I) and their use as FLT3 inhibitors for the treatment of various diseases, such as acute myeloid leukemia (AML). The present invention further relates to methods of synthesizing the compounds and methods of treatment.
    Type: Application
    Filed: August 9, 2018
    Publication date: June 18, 2020
    Inventors: SIAVOSH MAHBOOBI, ANDREAS SELLMER, HERWIG PONGRATZ, BERNARDETTE PILSL, OLIVER KRÄMER, THOMAS KINDLER, MANDY BEYER
  • HDAC6 inhibitors and their uses
    Patent number: 10106540
    Abstract: The present invention relates to small molecule compounds and their use as HDAC inhibitors and in the treatment of various diseases, such as cancer. The present invention further relates to methods of synthesizing the compounds and methods of treatment. H-L(HA), H is a head group selected from (head group 1), (head group 2), (head group 3), (head group 4), (head group 5) and (head group 6).
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: October 23, 2018
    Assignees: UNIVERSITÄT REGENSBURG, FRIEDRICH-SCHILLER-UNIVERSITÄT JENA, UNIVERSITÄTSKLINIKUM JENA
    Inventors: Siavosh Mahboobi, Andreas Sellmer, Herwig Pongratz, Michel Leonhardt, Oliver Krämer, Frank-Dietmar Böhmer, Gerhard Kelter
  • METHOD FOR RECOMBINANT PROTEIN PRODUCTION IN MAMMALIAN CELLS
    Publication number: 20180094258
    Abstract: Some embodiments relate to methods for the recombinant expression of a protein of interest in a mammalian host cell, use of an shRNA or an siRNA directed against the Galectin-1 gene for increasing the expression of a protein of interest in a mammalian host cell and kits comprising an shRNA or an siRNA and a CHO cell.
    Type: Application
    Filed: April 24, 2017
    Publication date: April 5, 2018
    Inventors: Thomas Noll, Oliver Krämer, Sandra Klausing
  • NOVEL HDAC6 INHIBITORS AND THEIR USES
    Publication number: 20170210743
    Abstract: The present invention relates to small molecule compounds and their use as HDAC inhibitors and in the treatment of various diseases, such as cancer. The present invention further relates to methods of synthesizing the compounds and methods of treatment. H-L(HA), H is a head group selected from (head group 1), (head group 2), (head group 3), (head group 4), (head group 5) and (head group 6).
    Type: Application
    Filed: August 4, 2015
    Publication date: July 27, 2017
    Inventors: Siavosh MAHBOOBI, Andreas SELLMER, Herwig PONGRATZ, Michel LEONHARDT, Oliver KRÄMER, Frank-Dietmar BÖHMER, Gerhard KELTER
  • METHOD FOR RECOMBINANT PROTEIN PRODUCTION IN MAMMALIAN CELLS
    Publication number: 20160152975
    Abstract: Some embodiments relate to methods for the recombinant expression of a protein of interest in a mammalian host cell, use of an sh RNA or an si RNA directed against the Galectin-1 gene for increasing the expression of a protein of interest in a mammalian host cell and kits comprising an shRNA or an si RNA and a CHO cell.
    Type: Application
    Filed: July 23, 2014
    Publication date: June 2, 2016
    Inventors: Thomas Noll, Oliver Krämer, Sandra Klausing